Erythropoietin

"Cellular and Molecular Biology of Erythropoietin Mammalian Transcription Factors and Their Interaction with Enhancers and Promoters, K Seipel, O. Georgiev, D. N. Arnosti, and W. Schaffner Regulation of Human Erythropoietin Gene Expression in Transgenic Mice and Human Hepatoma Cells, G. L. Semenza Discussion Inducible Operation of the Erythropoietin 3' Enhancer in Different Cell Lines: Evidence for a Widespread Oxygen-Sensing Mechanism in Mammalian Cells, C. W. Pugh, P. H. Maxwell, L. G. Nicholls, O. Ebrahim, S. M. Bartlett, and P. J. Ratcliffe Discussion DNA/Protein Interactions on the Human Erythropoietin Enhancer, A. M. Acquaviva and K. L. Blanchard Discussion Localization of Erythropoietin-Producing Cells in the Livers and Kidneys of Transgenic Mice, S. T. Koury and G. L. Semenza Discussion Accumulation of Erythopoietin mRNA in Rat Liver and Kidneys, K.-U. Eckardt, C. C. Tan, P. J. Ratcliffe, and A. Kurtz Discussion Physiological Functions Under rhEPO Therapy Measurement of Quality of Life in International Trials Involving Dialysis Patients and the Use of Recombinant Human Erythropoietin, R. M. Lindsay and A. P. Heidenheim Discussion Anemia and the Heart, M. Leschke, F. Schoebel, and B. E. Strauer Discussion Recombinant Human Erythropoietin Therapy: Benefits for the Heart and Physical Performance, K. M. L. Leunissen, J. J. J. M. Wirtz, W. van Kuijk, and J. P. van Hooff Discussion Erythropoietin and Hypertension, J. Radermacher and K. M. Koch Discussion Long-Term Changes of a2 Receptors in Recombinant Human Erythropoietin-Corrected Anemia, M. Pollok, H. M. Steffen, R. Muller, H. P. Behrenbeck, and C. A. Baldamus Discussion Iron and Erythropoiesis, J. W. Adamson Discussion Influence of Recombinant Human Erythropoietin on Iron Metabolism in Healthy Subjects, B. S. Skikne and J. D. Cook Disturbances of Iron Metabolism in the Anemia of Chronic Disorders, J. P. Kaltwasser Discussion Iron Supplementation of Hemodialysis Patients Receiving Recombinant Human Erythropoietin Therapy, C. Granolleras, R. OulEs, B. Branger, J. Fourcade, and S. Shaldon Discussion Panel Discussion Nephrology Mechanism of Erythopoietin Action/Immunogenicity of rhEPO Intracellular Transduction of Erythropoietin Signal, I. Dusanter, O. Muller, M. Sabbah, S. Fischer, C. Lacombe, and P. Mayeux Discussion Is Erythropoietin a Differentiation Factor, a Mitotic Factor, or a Survival Factor?, M. Bondurant, L. Kelley, and M. J. Koury Discussion Erythropoietin's Signaling Pathways and Primary Response Genes as Targets for Pharmacological Agents, A. J. Sytkowski Discussion A Case of Antierythropoietin Antibodies Following Recombinant Human Erythropoietin Treatment, H. Bergrem, B. G. Danielson, K.-U. Eckardt, A. Kurtz, and M. Stridsberg Discussion rhEPO Therapy in Neoplastic Disease The Effects of Red Blood Cell Transfusion on Host Immune Function, T. Hirose, S. Pepkowitz, A. Jacobs, S. Nichols, S. Lee, T. Hodgson, C. Inducil, R. Gray, S. Kelly, C. Etzler, S. Epling, K. Miller, and D. Goldfinger Discussion Recombinant Human Erythropoietin in the Treatment of the Anemia Associated with Solid Tumors, D. H. Henry Anemia Associated with Cisplatin Chemotherapy, C. B. Miller and S. R. Mills Discussion Recombinant Human Erythropoietin in Hematological Malignancies, L. Ponchio, G. Farina, C. Pedrotti, V. Rosti, G. Bergamaschi, and M. Cazzola Discussion Recombinant Human Erythropoietin Therapy in Patients with Osteosarcoma and Ewing's Sarcoma, C. Wurnig, M. Keil, R. Windhager, A. Zoubek, J. Krugluger, E. Schwameis, J. Kirchheimer, and F. Stockenhuber Discussion Treatment of Myelodysplastic Syndromes with a Combination of Granulocyte Colony-Stimulating Factor and Erythropoietin E. HellstrOm-Lindberg, G. Birgegård, M. Carlsson, J. Carneskog, I.-M. Dahl, I. Dybedal, G. Grimfors, K. Merk, J.-M. Tangen, I. Winqvist, and Å. Ost Discussion Combined Use of Erythropoietin and Granulocyte-Macrophage-Colony-Stimulating Factor in Patients Undergoing Bone Marrow Transplantation: Preliminary Results of a Pilot Study, M. Abecasis and M. J. Passos Discussion Panel Discussion Oncology and Hematology Application of rhEPO in Premature Infants and During/After Pregnancy The Anemia of Prematurity: Causes and Therapeutic Consequences, D. S. Halpérin, M. FElix, P. Wacker, G. Lacourt, J.-F. Babel, and M. Wyss Discussion Is There a Need for Erythropoietin Treatment During and After Pregnancy?, R. Huch Discussion Use of rhEPO in Elective Surgery (Facilitation of Autologous Blood Donation, Transfusion Avoidance) Risks of Homologous Blood Transfusion, B. Kubanek Discussion The Rationale for Use of Recombinant Human Erythropoietin to Facilitate Autologous Blood Collection Before Elective Surgery, L. T. Goodnough Discussion Preoperative Autologous Blood Donation with rhEPO Therapy in Patients Scheduled for Cardiac Surgery: Preliminary Results of a Dose-Response Finding Multicenter Trial, H. G. Guse, K. Wens, W. Behr, K. Doukas, W. Franke, D. Messinger, and P. Scigalla Discussion Dose-Response Relationship of rhEPO in Preoperative Autologous Blood Donation in Patients Scheduled for Elective Orthopedic Surgery, P. M. Osswald, A. Osmers, A. Lorentz, W. Franke, D. Messinger, P. Scigalla, and P. Haux Erythropoiesis in Autologous Blood Donors Treated with Recombinant Human Erythropoietin, A. van de Wiel and D. H. Biesma Discussion Panel Discussion Elective Surgery (Autologous Blood Donations; Transfusion Avoidance) "